Publikationer av Amelie Eriksson Karlström
Refereegranskade
Artiklar
[1]
S. S. Sahu et al., "Multi-marker profiling of extracellular vesicles using streaming current and sequential electrostatic labeling," Biosensors & bioelectronics, vol. 227, 2023.
[2]
M. Oroujeni et al., "Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts," Journal of Nuclear Medicine, vol. 63, no. 7, s. 1046-1051, 2022.
[3]
M. Banijamali et al., "Characterizing single extracellular vesicles by droplet barcode sequencing for protein analysis," Journal of Extracellular Vesicles, vol. 11, no. 11, 2022.
[4]
J. Caers et al., "Radiotheranostic Agents in Hematological Malignancies," Frontiers in Immunology, vol. 13, 2022.
[5]
H. Tano et al., "Comparative Evaluation of Novel Lu-177-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting," Cancers, vol. 13, no. 3, 2021.
[6]
C. Stiller et al., "Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR," Cancers, vol. 13, no. 4, 2021.
[7]
S. S. Sahu et al., "Electrokinetic sandwich assay and DNA mediated charge amplification for enhanced sensitivity and specificity," Biosensors & bioelectronics, vol. 176, 2021.
[8]
S. S. Sahu et al., "Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor," ACS Applied Materials and Interfaces, vol. 13, no. 36, s. 42513-42521, 2021.
[9]
K. Westerlund et al., "Stability Enhancement of a Dimeric HER2-Specific Affibody Molecule through Sortase A-Catalyzed Head-to-Tail Cyclization," Molecules, vol. 26, no. 10, 2021.
[10]
A. Myrhammar et al., "Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting," Scientific Reports, vol. 10, no. 1, 2020.
[11]
S. S. Sahu et al., "Influence of molecular size and zeta potential in electrokinetic biosensing," Biosensors & bioelectronics, vol. 152, 2020.
[12]
A. Myrhammar, D. Rosik och A. Eriksson Karlström, "Photocontrolled Reversible Binding between the Protein A-Derived Z Domain and Immunoglobulin G," Bioconjugate chemistry, vol. 31, no. 3, s. 622-630, 2020.
[13]
A. Abouzayed et al., "Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer," Pharmaceutics, vol. 12, no. 10, 2020.
[14]
C. Stiller et al., "Fast and Efficient Fc-Specific Photoaffinity Labeling To Produce Antibody-DNA Conjugates," Bioconjugate chemistry, vol. 30, no. 11, s. 2790-2798, 2019.
[15]
S. Cavallaro et al., "Label-Free Surface Protein Profiling of Extracellular Vesicles by an Electrokinetic Sensor," ACS Sensors, vol. 4, no. 5, s. 1399-1408, 2019.
[16]
K. Westerlund et al., "Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting," Biomaterials, vol. 203, s. 73-85, 2019.
[17]
A. Vorobyeva et al., "Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy," Scientific Reports, vol. 8, no. 1, 2018.
[18]
V. Tolmachev et al., "Molecular design of radiocopper-labelled Affibody molecules," Scientific Reports, vol. 8, 2018.
[19]
K. Westerlund et al., "Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting : In Vivo Proof of Principle," Journal of Nuclear Medicine, vol. 59, no. 7, s. 1092-1098, 2018.
[20]
J. Horak et al., "Recombinant Spider Silk as Mediator for One-Step, Chemical-Free Surface Biofunctionalization," Advanced Functional Materials, vol. 28, no. 21, 2018.
[21]
S. Ståhl et al., "Affibody Molecules in Biotechnological and Medical Applications," Trends in Biotechnology, vol. 35, no. 8, s. 691-712, 2017.
[22]
V. Tolmachev et al., "Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with Cu-64 Using NOTA and NODAGA," Contrast Media & Molecular Imaging, s. 1-12, 2017.
[23]
M. Altai et al., "Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting : Development of an optimized conjugation protocol and 177Lu labeling," Nuclear Medicine and Biology, vol. 54, s. 1-9, 2017.
[24]
H. Honarvar et al., "Evaluation of the first Sc-44-labeled Affibody molecule for imaging of HER2-expressing tumors," Nuclear Medicine and Biology, vol. 45, s. 15-21, 2017.
[25]
A. Nilsson, J. Lindgren och A. Eriksson Karlström, "Intramolecular Thioether Crosslinking to Increase the Proteolytic Stability of Affibody Molecules," ChemBioChem (Print), vol. 18, no. 20, s. 2056-2062, 2017.
[26]
M. Altai et al., "Comparative evaluation of Lu-177-HP2 and In-111-HP2, secondary agents for affibody-based PNA-mediated radionuclide pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, s. S237-S237, 2016.
[27]
H. Honarvar et al., "Development and application of first Sc-44-labeled Affibody molecule," European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, s. S177-S177, 2016.
[28]
A. Dev et al., "Electrokinetic effect for molecular recognition : A label-free approach for real-time biosensing," Biosensors & bioelectronics, vol. 82, s. 55-63, 2016.
[29]
H. Honarvar et al., "Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors," Theranostics, vol. 6, no. 1, s. 93-103, 2016.
[30]
M. Altai et al., "Feasibility of Affibody-Based Bioorthogonal Chemistry Mediated Radionuclide Pretargeting," Journal of Nuclear Medicine, vol. 57, no. 3, s. 431-436, 2016.
[31]
K. Westerlund et al., "Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules," Molecular Pharmaceutics, vol. 13, no. 5, s. 1668-1678, 2016.
[32]
A. Tiiman et al., "Specific Binding of Cu(II) Ions to Amyloid-Beta Peptides Bound to Aggregation-Inhibiting Molecules or SDS Micelles Creates Complexes that Generate Radical Oxygen Species," Journal of Alzheimer's Disease, vol. 54, no. 3, s. 971-982, 2016.
[33]
M. Altai et al., "Affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting : proof-of-principle.," European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, s. S246-S246, 2015.
[34]
K. Westerlund et al., "Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting," Bioconjugate chemistry, vol. 26, no. 8, s. 1724-1736, 2015.
[35]
R. Afrasiabi et al., "Effect of microwave-assisted silanization on sensing properties of silicon nanoribbon FETs," Sensors and actuators. B, Chemical, vol. 209, s. 586-595, 2015.
[36]
A. Perols, M. Arcos Famme och A. Eriksson Karlström, "Site-specific antibody labeling by covalent photoconjugation of Z domains functionalized for alkyne-azide cycloaddition reactions," ChemBioChem (Print), vol. 16, no. 17, s. 2522-2529, 2015.
[37]
J. Lindgren et al., "A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life," Biopolymers, vol. 102, no. 3, s. 252-259, 2014.
[38]
D. Rosik et al., "Incorporation of a Triglutamyl Spacer Improves the Biodistribution of Synthetic Affibody Molecules Radiofluorinated at the N-Terminus via Oxime Formation with F-18-4-Fluorobenzaldehyde," Bioconjugate chemistry, vol. 25, no. 1, s. 82-92, 2014.
[39]
D. Rönnlund et al., "Multicolor Fluorescence Nanoscopy by Photobleaching : Concept Verification and its Application to Resolve Selective Storage of Proteins in Platelets," ACS Nano, vol. 8, no. 5, s. 4358-4365, 2014.
[40]
H. Honarvar et al., "Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga-Compared to 111in-labeled conjugates," Molecular Imaging, vol. 13, no. 10, 2014.
[41]
A. Perols och A. Eriksson Karlström, "Site-Specific Photoconjugation of Antibodies Using Chemically Synthesized IgG-Binding Domains," Bioconjugate chemistry, vol. 25, no. 3, s. 481-488, 2014.
[42]
J. Lindgren et al., "Engineered non-fluorescent Affibody molecules facilitate studies of the amyloid-beta (A beta) peptide in monomeric form : Low pH was found to reduce A beta/Cu(II) binding affinity," Journal of Inorganic Biochemistry, vol. 120, s. 18-23, 2013.
[43]
H. Honarvar et al., "Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging," Nuclear Medicine and Biology, vol. 40, no. 3, s. 378-386, 2013.
[44]
J. Strand et al., "Influence of Macrocyclic Chelators on the Targeting Properties of Ga-68-Labeled Synthetic Affibody Molecules : Comparison with In-111-Labeled Counterparts," PLOS ONE, vol. 8, no. 8, s. e70028, 2013.
[45]
M. Altai et al., "Influence of Nuclides and Chelators on Imaging Using Affibody Molecules : Comparative Evaluation of Recombinant Affibody Molecules Site-Specifically Labeled with Ga-68 and In-111 via Maleimido Derivatives of DOTA and NODAGA," Bioconjugate chemistry, vol. 24, no. 6, s. 1102-1109, 2013.
[46]
N. Jokilaakso et al., "Ultra-localized single cell electroporation using silicon nanowires," Lab on a Chip, vol. 13, no. 3, s. 336-339, 2013.
[47]
J. Lindgren et al., "A Native Chemical Ligation Approach for Combinatorial Assembly of Affibody Molecules," ChemBioChem (Print), vol. 13, no. 7, s. 1024-1031, 2012.
[48]
M. Altai et al., "Comparative evaluation of anti-HER2 affibody molecules labeled with 68Ga and 111In using maleimido derivatives of DOTA and NODAGA.," European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, s. S299-S299, 2012.
[49]
J. Malmberg et al., "Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with In-111 using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts," European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 3, s. 481-492, 2012.
[50]
D. Rosik et al., "Direct comparison of In-111-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging," European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 4, s. 693-702, 2012.
[51]
A. Perols et al., "Influence of DOTA Chelator Position on Biodistribution and Targeting Properties of In-111-Labeled Synthetic Anti-HER2 Affibody Molecules," Bioconjugate chemistry, vol. 23, no. 8, s. 1661-1670, 2012.
[52]
M. Altai et al., "Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with In-111 using a maleimido derivative of NODAGA," Nuclear Medicine and Biology, vol. 39, no. 4, s. 518-529, 2012.
[53]
P. Järver, C. Mikaelsson och A. Karlstrom Eriksson, "Chemical synthesis and evaluation of a backbone-cyclized minimized 2-helix Z-domain," Journal of Peptide Science, vol. 17, no. 6, s. 463-469, 2011.
[54]
A. Konrad, A. Eriksson Karlström och S. Hober, "Covalent Immunoglobulin Labeling through a Photoactivable Synthetic Z Domain," Bioconjugate chemistry, vol. 22, no. 12, s. 2395-2403, 2011.
[55]
S. Chen et al., "Current Instability for Silicon Nanowire Field-Effect Sensors Operating in Electrolyte with Platinum Gate Electrodes," Electrochemical and solid-state letters, vol. 14, no. 7, s. J34-J37, 2011.
[56]
V. Tolmachev et al., "Evaluation of a Maleimido Derivative of NOTA for Site-Specific Labeling of Affibody Molecules," Bioconjugate chemistry, vol. 22, no. 5, s. 894-902, 2011.
[57]
S. Chen et al., "A two-terminal silicon nanoribbon field-effect pH sensor," Applied Physics Letters, vol. 97, no. 26, s. 264102, 2010.
[58]
J. Lindgren et al., "N-terminal engineering of amyloid-beta-binding Affibody molecules yields improved chemical synthesis and higher binding affinity," Protein Science, vol. 19, no. 12, s. 2319-2329, 2010.
[59]
A. Orlova et al., "Re-186-maSGS-Z(HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours," European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 2, s. 260-269, 2010.
[60]
T. Ekblad et al., "Positioning of Tc-99m-chelators influences radiolabeling, stability and biodistribution of Affibody molecules," Bioorganic & Medicinal Chemistry Letters, vol. 19, no. 14, s. 3912-3914, 2009.
[61]
T. Ekblad et al., "Synthesis and chemoselective intramolecular crosslinking of a HER2-binding Affibody," Biopolymers, vol. 92, no. 2, s. 116-123, 2009.
[62]
T. Ekblad et al., "Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake," European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 12, s. 2245-2255, 2008.
[63]
T. A. Tran et al., "Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of Tc-99m-Labeled Anti-HER2 Affibody Molecules," Bioconjugate chemistry, vol. 19, no. 12, s. 2568-2576, 2008.
[64]
M. G. Bjorklund et al., "Microarray analysis using disiloxyl 70mer oligonucleotides," Nucleic Acids Research, vol. 36, no. 4, s. 1334-1342, 2008.
[65]
N. Elfström, A. Eriksson Karlström och J. Linnros, "Silicon Nanoribbons for Electrical Detection of Biomolecules," Nano letters (Print), vol. 8, no. 3, s. 945-949, 2008.
[66]
T. Engfeldt et al., "99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule," European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 11, s. 1843-1853, 2007.
[67]
T. Tran et al., "99mTc-maEEE-ZHER2:342, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors," Bioconjugate chemistry, vol. 18, no. 6, s. 1956-1964, 2007.
[68]
B. Renberg et al., "Affibody molecules in protein capture microarrays : Evaluation of multidomain ligands and different detection formats," Journal of Proteome Research, vol. 6, no. 1, s. 171-179, 2007.
[69]
T. Engfeldt et al., "Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence," European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 5, s. 722-733, 2007.
[70]
T. Tran et al., "In vivo evaluation of cysteine-based chelators for attachment of Tc-99m to tumor-targeting affibody molecules," Bioconjugate chemistry, vol. 18, no. 2, s. 549-558, 2007.
[71]
A. Orlova et al., "Pre-clinical evaluation of -benzyl-DOTA-ZHER2 : 3429 a potential agent for imaging of HER2 expression in malignant tumors," International Journal of Molecular Medicine, vol. 20, no. 3, s. 397-404, 2007.
[72]
N. Elfström et al., "Surface Charge Sensitivity of Silicon Nanowires : Size Dependence," Nano letters (Print), vol. 7, no. 9, s. 2608-2612, 2007.
[73]
B. Renberg et al., "Affibody protein capture microarrays : synthesis and evaluation of random and directed immobilization of affibody molecules," Analytical Biochemistry, vol. 341, no. 2, s. 334-343, 2005.
[74]
T. Engfeldt et al., "Chemical Synthesis of Triple-Labelled Three-Helix Bundle Binding Proteins for Specific Fluorescent Detection of Unlabelled Protein," ChemBioChem (Print), vol. 6, no. 6, s. 1043-1050, 2005.
[75]
B. Renberg et al., "Fluorescence resonance energy transfer-based detection of analytes using antiidiotypic affinity protein pairs," Analytical Biochemistry, vol. 334, no. 1, s. 72-80, 2004.
Konferensbidrag
[76]
J. Horak et al., "Recombinant spider silk as mediator for one-step, chemical-free surface biofunctionalization.," i Biosensors 2018, June 2018, Miami, Florida, USA., 2018.
Kapitel i böcker
[77]
M. Altai et al., "Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting," i Methods in Molecular Biology, : Humana Press Inc., 2020, s. 283-304.
Icke refereegranskade
Artiklar
[78]
M. Oroujeni et al., "Combined treatment of mice bearing HER2-expressing xenografts by trastuzumab and Affibody-mediated PNA-based pretargeting improves their survival," European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. SUPPL 1, s. S158-S158, 2021.
[79]
M. Oroujeni et al., "Comparative evaluation of novel Lu-177-labeled PNA conjugates for affibody mediated PNA-based pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. SUPPL 1, s. S344-S344, 2020.
[80]
A. Abouzayed et al., "Conjugation of GRPR-targeting antagonist RM26 to albumin-binding domain extends antagonist's blood circulation and residence in tumours," European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. SUPPL 1, s. S652-S652, 2020.
[81]
M. Altai et al., "Design and evaluation oflactosaminated cetuximabas a clearing agent for antibody-based PNA-mediated pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. SUPPL 1, s. S343-S344, 2020.
[82]
M. Altai et al., "A novel method for conjugation of PNA to antibodies for radionuclide based pretargeting : proof of principal," European Journal of Nuclear Medicine and Molecular Imaging, vol. 45, s. S648-S648, 2018.
[83]
A. Vorobyeva et al., "Development of a PET Imaging Approach for Selection of Patients for Affibody-Based PNA-Mediated Pretargeted Radionuclide Therapy," European Journal of Nuclear Medicine and Molecular Imaging, vol. 45, s. S104-S104, 2018.
[84]
V. Tolmachev et al., "Evaluation of NOTA and NODAGA for labelling of affibody molecules with radiocopper," Journal of labelled compounds & radiopharmaceuticals, vol. 60, s. S230-S230, 2017.
[85]
A. Vorobyeva et al., "Feasibility of Z Domain-Mediated Conjugation of PNA to Antibodies for Radionuclide Pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, s. S559-S560, 2017.
[86]
V. Tolmachev et al., "Optimal molecular design of radiocopper-labelled affibody molecules," European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, s. S549-S549, 2017.
[87]
M. Altai et al., "Pretargeted radionuclide therapy of HER2-expressing SKOV-3 human xenografts using an Affibody molecule-based PNA-mediated pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, s. S142-S142, 2017.
[88]
J. Lindgren och A. Eriksson Karlström, "Intramolecular thioether crosslinking of therapeutic proteins to increase proteolytic stability," ChemBioChem (Print), vol. 15, no. 14, s. 2132-2138, 2014.
[89]
J. Malmberg et al., "Evaluating the effect of the chelator on biodistribution of a HER2 imaging agent : DOTA conjugated anti-HER2 Affibody molecule outperforms NODAGA and NOTA in mice bearing prostate cancer xenografts," Journal of Nuclear Medicine, vol. 53, 2012.
[90]
A. Perols och A. Eriksson Karlström, "Chemical Synthesis of Fluorescent-Labeled Affibody Molecules for Use in Cancer Diagnostics," Journal of Peptide Science, vol. 16, s. 77-77, 2010.
[91]
S. Lindgren et al., "Engineering of Amyloid-beta-Binding Affibody Molecules for Improved Chemical Synthesis and Higher Binding Affinity," Journal of Peptide Science, vol. 16, s. 77-77, 2010.
[92]
P. J. Järver et al., "Synthesis and Biophysical Characterization of a Backbone-Cyclized Minimized Z Domain," Journal of Peptide Science, vol. 16, s. 62-62, 2010.
Övriga
[93]
E. Duray et al., "Development of an anti-CD38 single domain antibody fragment mediated PNA-based pretargeting strategy," (Manuskript).
[94]
M. Gestin et al., "Evaluation of the impact of length of peptide nucleic acid probes for tumor pretargeting," (Manuskript).
[95]
[96]
R. Afrasiabi et al., "Microwave-assisted silanization of SiNW-FET : characterization and effect on sensing properties," (Manuskript).
[97]
A. Konrad et al., "Optimization of an antibody labeling strategy through the use of photoactivable synthetic Z domains," (Manuskript).
[98]
N. Jokilaakso et al., "Spot-on functionalization of SiO2 for multiplexed silicon nanowire-FET biosensors," (Manuskript).
[99]
K. Westerund et al., "Stability enhancement of a dimeric HER2-specific Affibody molecule through sortase A-catalyzed head-to-tail cyclization," (Manuskript).
Patent
Patent
[100]
J. Caers et al., "Anti-Cd38 Single-Domain Antibodies in Disease Monitoring and Treatment," US 2023/0190968 A1 (2023-06-22), 2023.
Senaste synkning med DiVA:
2024-05-02 00:01:13